<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>1</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Noncoding RNAs and Cancer</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>55</FirstPage>
			<LastPage>70</LastPage>
			<ELocationID EIdType="pii">249625</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mozhgan</FirstName>
					<LastName>Moslemi Naeini</LastName>
<Affiliation>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Ali</FirstName>
					<LastName>M. Ardekani</LastName>
<Affiliation>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2009</Year>
					<Month>08</Month>
					<Day>10</Day>
				</PubDate>
			</History>
		    <Abstract>The eukaryotic complexity involves the expression and regulation of genes via RNA-DNA, RNA-RNA, DNA-protein and RNA-protein interactions. Recently, the role of RNA molecules in the regulation of genes in higher organisms has become more evident, especially with the discovery that about 97% of the transcriptional output in higher organisms are represented as noncoding RNAs: rRNA, snoRNAs, tRNA, transposable elements, 5&#039; and 3&#039; untranslated regions, introns, intergenic regions and microRNAs. MicroRNAs function by negatively regulating gene expression via degradation or translational inhibition of their target mRNAs and thus participate in a wide variety of physiological and pathological cellular processes including: development, cell proliferation, differentiation, and apoptosis pathways. MicroRNA expression profiles in many types of cancers have been identified. Recent reports have revealed that the expression profiles of microRNAs change in various human cancers and appear to function as oncogenes or tumor suppressors. Abnormal microRNA expression has increasingly become a common feature of human cancers. In this review, we summarize the latest progress on the involvement of microRNAs in different types of cancer and their potential use as potential diagnostic and prognostic tumor biomarkers in the future.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Biomarker</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cellular process</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Expression</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">micro RNA</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Noncoding RNA</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_249625_f088cc3fb4324c2125cb4ef2cdd55716.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>1</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>DNA Immunization as an Efficient Strategy for Vaccination</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>71</FirstPage>
			<LastPage>88</LastPage>
			<ELocationID EIdType="pii">249626</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Azam</FirstName>
					<LastName>Bolhassani</LastName>
<Affiliation>Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Sima</FirstName>
					<LastName>Rafati Yazdi</LastName>
<Affiliation>Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2009</Year>
					<Month>04</Month>
					<Day>22</Day>
				</PubDate>
			</History>
		    <Abstract>The field of vaccinology provides excellent promises to control different infectious and non-infectious diseases. Genetic immunization as a new tool in this area by using naked DNA has been shown to induce humoral as well as cellular immune responses with high efficiency. This demonstrates the enormous potential of this strategy for vaccination purposes. DNA vaccines have been widely used to develop vaccines against various pathogens as well as cancer, autoimmune diseases and allergy. However, despite their successful application in many pre-clinical disease models, their potency in human clinical trials has been insufficient to provide protective immunity. Several strategies have been applied to increase the potency of DNA vaccine. Among these strategies, the linkage of antigens to Heat Shock Proteins (HSPs) and the utilization of different delivery systems have been demonstrated as efficient approaches for increasing the potency of DNA vaccines. The uptake of DNA plasmids by cells upon injection is inefficient. Two basic delivery approaches including physical delivery to achieve higher levels of antigen production and formulation with micropajmb_articles to target Antigen-Presenting Cells (APCs) are effective in animal models. Alternatively, different regimens called prime-boost vaccination are also effective. In this regimen, naked DNA is utilized to prime the immune system and either recombinant viral vector or purified recombinant protein with proper adjuvant is used for boosting. In this review, we discuss recent advances in upgrading the efficiency of DNA vaccination in animal models.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">adjuvant</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Delivery System</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">DNA vaccination</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Infectious Disease</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prime</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">boost vaccination</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_249626_56107ba12457c5c13abde8216eb8fd1b.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>1</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Biotechnology-Related Intellectual Property Law of Iran</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>89</FirstPage>
			<LastPage>94</LastPage>
			<ELocationID EIdType="pii">249627</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mohammad</FirstName>
					<LastName>Rasekh</LastName>
<Affiliation>Faculty of Law, Shahid Beheshti University, Tehran, Iran; Bio Law and Ethics Department, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2009</Year>
					<Month>09</Month>
					<Day>05</Day>
				</PubDate>
			</History>
		    <Abstract>In this study, an attempt has been made to expound the Iranian law of intellectual property in relation to biotechnology. The most important themes studied are patents, industrial designs and trade marks. The latest relevant piece of legislation concerning the subject matters was passed in March 2008. However, the history of laws and regulations in this field goes back to early twentieth century (i.e. 1925). In this review, on the basis of the latest law passed in 2008, the topics explored are the responsible authority, patentable items and criteria, excluded items, registration procedure, rights conferred and sanctions. At the end, an attempt is made to put forward a few points as an analysis of the above Law from a critical point of view.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Biotechnology</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Industrial design</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">IP rights</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Iran IP law</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Patent</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Trade mark</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_249627_988acf3412f4cc55da3cbaecac3c885a.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>1</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Forward Modeling of the Coumarin Antifungals; SPR/SAR Based Perspective</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>95</FirstPage>
			<LastPage>103</LastPage>
			<ELocationID EIdType="pii">249628</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Saeed</FirstName>
					<LastName>Soltani</LastName>
<Affiliation>Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Shima</FirstName>
					<LastName>Dianat</LastName>
<Affiliation>Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Soroush</FirstName>
					<LastName>Sardari</LastName>
<Affiliation>Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2009</Year>
					<Month>03</Month>
					<Day>04</Day>
				</PubDate>
			</History>
		    <Abstract>Although, coumarins are a group of compounds which are naturally found in some plants, they can be synthetically produced as well. Because of their diverse derivatives, origin and properties most of them can be used for medicinal purposes. For example, they can be used against fungal diseases or in studying structure and biological properties of antifungal agents to discover new compounds with the similar activity. A Structure Property/Activity Relationship (SAR) can be utilized in prediction of biological activity of desired molecules.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Antifungal activity</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Coumarin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Modeling</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Neural Network</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_249628_981826e298a40b26901fdf54945ac59c.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>1</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The Anticancer Activity Compared Between Triptorelin and a New Gonadotropin Releasing Hormone Analogue</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>105</FirstPage>
			<LastPage>110</LastPage>
			<ELocationID EIdType="pii">249621</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mohammad</FirstName>
					<LastName>Mirzaei Saleh-Abady</LastName>
<Affiliation>Department of Biophysics, School of Basic Science, Tarbiat Modares University, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Abdolali</FirstName>
					<LastName>Alizadeh</LastName>
<Affiliation>Department of Organic Chemistry, School of Basic Science, Tarbiat Modares University, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Fereshteh</FirstName>
					<LastName>Shamsipour</LastName>
<Affiliation>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Hossein</FirstName>
					<LastName>Naderi-Manesh</LastName>
<Affiliation>Department of Biophysics, School of Basic Science, Tarbiat Modares University, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>26</Day>
				</PubDate>
			</History>
		    <Abstract>Gonadotropin releasing hormone (GnRH) plays a key role in reproduction. This decapeptide is synthesized and released by hypothalamus and induces the pituitary gonadotrop cells to release pituitary gonadotropin hormones. In some extrapituitary compartments GnRH and its receptor act as part of the autocrine regulatory system of cell proliferation. The anticancer activity of GnRH and its analogues has been observed by many researchers. In this study the anticancer activity of a new analogue of GnRH and triptorelin was investigated by cell proliferation assay. Results indicate that proliferation of human breast and ovarian cancer cell lines are dose-dependently inhibited. The inhibitory efficiency of the new analogue is proved to be higher than the original triptorelin. In addition to its antimitogenic activity, evidence was found for the involvement of the apoptotic mechanism in the action of the new analogue and triptorelin. In conclusion, the new analogue can be considered as a good pharmaceutical candidate.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">anticancer activity</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">breast cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">LHRH analogue</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">ovarian cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Peptidomimetics</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Triptorelin</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_249621_8f59c2b0e1a6231b022ea0e00ea902bc.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>1</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Green Synthesis of Small Silver Nanopajmb_articles Using Geraniol and Its Cytotoxicity against Fibrosarcoma-Wehi 164</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>111</FirstPage>
			<LastPage>115</LastPage>
			<ELocationID EIdType="pii">249622</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mona</FirstName>
					<LastName>Safaepour</LastName>
<Affiliation>Department of Pharmaceutical Biotechnology and Biotechnology Research center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Ahmad Reza</FirstName>
					<LastName>Shahverdi</LastName>
<Affiliation>Department of Pharmaceutical Biotechnology and Biotechnology Research center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Hamid Reza</FirstName>
					<LastName>Shahverdi</LastName>
<Affiliation>Department of Material Science, Faculty of Engineering, Tarbiat Modares University, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mohammad Reza</FirstName>
					<LastName>Khorramizadeh</LastName>
<Affiliation>Department of Pathobiology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Ahmad Reza</FirstName>
					<LastName>Gohari</LastName>
<Affiliation>Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2009</Year>
					<Month>04</Month>
					<Day>27</Day>
				</PubDate>
			</History>
		    <Abstract>Many reports have been published about the biogenesis of silver nanopajmb_articles using several plant extracts such as Pelargonium graveolens (P.graveolens- geranium) and Azadirachta indica (neem) but the capacity of their natural reducing constituents to form silver nanopajmb_articles has not yet been studied. In this research the synthesis of silver nanopajmb_articles using geraniol has been investigated. We successfully synthesized uniformly dispersed silver nanopajmb_articles with a uniform size and shape in the range of 1 to 10 nm with an average size of 6 nm. Also the cytotoxicity of the prepared silver nanopajmb_articles was investigated using a cancer cell line (Fibrosarcoma-Wehi 164). The cytotoxicity analysis of the sample shows a direct dose-response relationship; cytotoxicity increased at higher concentrations. At concentration of 1 µg/ml, silver nanopajmb_articles was able to inhibit the cell line’s growth by less than 30%. Conversly, the presence of 5 µg/ml of silver nanoparticlse significantly inhibited the cell line’s growth (&gt; 60%). The concentration necessary to produce 50% cell death was 2.6 µg/ml for this silver nanopajmb_articles preapared with geraniol.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Fibrosarcoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Wehi 164</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Geraniol</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Green synthesis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Silver nanoparticle</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_249622_79260e9cff857983445cd384ee59cc8a.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>1</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>New Variations in the Promoter Regions of Human DOCK4 and RAP1A Genes, and Coding Regions of RAP1A in Sporadic Breast Tumors</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>117</FirstPage>
			<LastPage>123</LastPage>
			<ELocationID EIdType="pii">249623</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Akram</FirstName>
					<LastName>Jalali</LastName>
<Affiliation>Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Hassan</FirstName>
					<LastName>Ebrahimi</LastName>
<Affiliation>Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mina</FirstName>
					<LastName>Ohadi</LastName>
<Affiliation>Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Masood</FirstName>
					<LastName>Karimloo</LastName>
<Affiliation>Epidemiology and Biostatistics Department, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Atena</FirstName>
					<LastName>Irani Shemirani</LastName>
<Affiliation>Reproductive Biotechnology Research Centre, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Behrokh</FirstName>
					<LastName>Mohajer Maghari</LastName>
<Affiliation>Reproductive Biotechnology Research Centre, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Hamid Reza</FirstName>
					<LastName>Khorram Khorshid</LastName>
<Affiliation>Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; Reproductive Biotechnology Research Centre, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2009</Year>
					<Month>02</Month>
					<Day>05</Day>
				</PubDate>
			</History>
		    <Abstract>Breast cancer is the most common cancer among women in developed countries. The prevalence of the disease is increasing in the world. Its annual incidence among Iranian women is about 7000 cases. RAP1A, a tumor suppressor gene, is located at 1p13.3 and plays an important role in the cellular adhesion pathway and is involved in the pathogenesis of breast cancer. The DOCK4 gene, which is located at 7q31.1, specifically activates RAP1A gene. In the present study, DNA samples from 64 cases of sporadic breast tumors (referred to Mehrad Hospital in Tehran) were screened using PCR-SSCP method and the number of observed variations compared with the control group (100 normal women). Mutation detection for coding exons of RAP1A gene and the 500 bp upstream of transcription initiation site as promoters of both DOCK4 and RAP1A were carried out and compared with the control group. The promoter region of DOCK4 showed a heterozygous mutation with G&gt;A transition at nucleotide -303 in a fibroadenoma case. With regard to RAP1A we found a heterozygous mutation, G&gt;A transition in an adenoid cystic carcinoma case, and another heterozygous mutation, G&gt;T transversion in an intraductal papilloma case both at nucleotide +45. A homozygous variation, T&gt;A transversion was also found at nucleotide +29 of a fibroadenoma case. The differences in the frequency of variations mentioned above were not statistically significant. However Fisher’s exact showed significant difference for T&gt;A transversion. Although, the higher frequency of these mutations and variations may be related to the disease, a larger sample size is needed for the confirmation of our findings.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">DOCK4</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Loss of heterozygosity (LOH)</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">PCR</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">SSCP</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">RAP1A</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Sporadic breast tumor</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_249623_99ca26eb1a8e8563e5b727e26207e4c4.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>1</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>125</FirstPage>
			<LastPage>131</LastPage>
			<ELocationID EIdType="pii">249624</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Shayda</FirstName>
					<LastName>Hemmati</LastName>
<Affiliation>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran; Department of Cell and Molecular Biology, Khatam University, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Amir-Hassan</FirstName>
					<LastName>Zarnani</LastName>
<Affiliation>Nanobiotechnology Research Center, Avicenna Research Institute, Tehran, Iran; Immunology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Ahmad Reza</FirstName>
					<LastName>Mahmoudi</LastName>
<Affiliation>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mohammad Reza</FirstName>
					<LastName>Sadeghi</LastName>
<Affiliation>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Haleh</FirstName>
					<LastName>Soltanghoraee</LastName>
<Affiliation>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mohammad Mehdi</FirstName>
					<LastName>Akhondi</LastName>
<Affiliation>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Majid</FirstName>
					<LastName>Tarahomi</LastName>
<Affiliation>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mahmood</FirstName>
					<LastName>Jeddi-Tehrani</LastName>
<Affiliation>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran; Immune and Gene Therapy Lab, CCK, Department of Oncology-Pathology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Swe</Affiliation>

</Author>
<Author>
					<FirstName>Hodjattallah</FirstName>
					<LastName>Rabbani</LastName>
<Affiliation>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran; Immune and Gene Therapy Lab, CCK, Department of Oncology-Pathology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Swe</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2009</Year>
					<Month>08</Month>
					<Day>31</Day>
				</PubDate>
			</History>
		    <Abstract>Gene expression profiling of ovarian carcinoma tissues has shown an increase of four-fold expression of SORT1 gene. Sortilin 1 (NTR-3) is a 95-100 kDa protein normally expressed in heart, brain, placenta, skeletal muscle, spinal cord, thyroid, and testis. However, its expression has never been reported in normal ovary. Here, we report expression of sortilin 1 in ovarian carcinoma tissues both at gene and protein levels. Sortilin 1 was expressed in all ovarian carcinoma patients (n=15) as well as ovarian carcinoma cell lines (n=5) regardless of their phenotypic characteristics. Non-malignant ovaries (n=6) did not express sortilin 1. The molecular basis for this ectopic expression is not yet clear. Our results showed a major cell surface expression of sortilin 1 rather than ER-Golgi compartment where it is mainly expressed. This finding may introduce sortilin 1 as a novel tumor marker for diagnosis of ovarian carcinoma and may signify its therapeutic value in targeted therapy.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">ectopic</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Expression</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">NTR</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">ovarian carcinoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Sortilin</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_249624_fbea7d5d04b719473ff32ef14a49e865.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
